R&D Tax Credit

The Research and Development (R&D) tax credit — codified at 26 U.S.C. § 41 — provides a dollar-for-dollar federal income tax credit for qualified research expenditures, reducing the after-tax cost of developing new or improved products, processes, and software. The regular credit rate is 20% of qualified expenses above a base amount; the more commonly used Alternative Simplified Credit (ASC) is 14% of spending above 50% of the prior 3-year average. For qualified startups ($5 million or less in gross receipts), up to $500,000 of the credit can offset payroll taxes rather than income tax — making it valuable even before a company turns profitable. The credit's value was complicated dramatically in 2022: a longstanding provision allowing immediate expensing of R&D costs under IRC § 174 was replaced by mandatory 5-year amortization (15 years for foreign research), meaning companies now capitalize and slowly deduct research costs rather than deducting them immediately — raising near-term tax bills even as the credit remains available. Reversing the § 174 change has been a top priority for technology and pharmaceutical industry lobbying, with bipartisan support for restoration but persistent gridlock over revenue offsets.

Current Law (2026)

The research and development tax credit provides a credit for qualified research expenses, but since 2022, R&D costs must be amortized over 5 years (15 years for foreign research) rather than expensed immediately.

Key Numbers

• 20% regular credit rate on qualified research expenses above a calculated base; 14% Alternative Simplified Credit (ASC) on expenses above 50% of the prior 3-year average — the ASC is more commonly used because the base period calculation for the regular method is complex and often produces a higher effective rate on additional spending rather than total spending
• $500,000 payroll tax offset for eligible startups: companies with gross receipts of $5 million or less that have not had gross receipts for any tax year before the 5-year period ending with the current tax year can apply up to $500,000 of R&D credit against FICA payroll tax (expanded from $250,000 by the Inflation Reduction Act); this makes the credit valuable to pre-revenue startups that owe no income tax
• 5-year domestic amortization under IRC § 174 (since tax year 2022): a company spending $2 million on domestic R&D can deduct only $400,000 in year one (one-fifth of the midpoint-convention calculation = actually ~$200K in year 1 under half-year convention), significantly reducing available deductions; 15-year amortization for foreign research — making offshore R&D dramatically more expensive from a tax perspective
• Cash tax impact of §174: for a company with $1M in R&D and $800K in revenue that would have been a cash-loss business pre-2022, it is now technically profitable for tax purposes (because only ~$100-200K of R&D is deductible in year 1); some companies have reported owing $100,000+ in unexpected tax bills on operations they consider loss-making; the effect is largest in year 1 and diminishes as prior-year amortization pools build up
• Total R&D tax credits claimed: approximately $17–20 billion per year across all U.S. businesses — making it one of the largest single business tax incentives in the federal tax code, comparable in aggregate value to accelerated depreciation provisions
• Software development wages qualify: engineers, developers, data scientists writing new code for new products or substantially improved processes qualify — the single most common application of the R&D credit for technology companies, where payroll is the dominant R&D cost
• Bipartisan support for §174 fix: the Tax Relief for American Families and Workers Act (passed House 357-70 in February 2024 before stalling in Senate) included §174 immediate expensing restoration retroactive to 2022; similar provisions in HR 1990 and S 1639 in the 119th Congress (2025-2026)

Legal Authority

• 26 U.S.C. § 41 — Credit for increasing research activities
• IRC Section 174 — Research and experimental expenditures

How It Works

The credit under 26 U.S.C. § 41 applies to "qualified research activities" — a four-part test: the work must be technological in nature, aimed at developing new or improved products or processes, involve genuine technical uncertainty, and follow a process of experimentation rather than educated guessing. Software development typically satisfies all four prongs, making engineer and developer wages the most common qualifying expense for technology companies.

The 2022 change that has hit R&D-intensive businesses hardest is mandatory amortization under IRC § 174: rather than deducting R&D expenditures immediately, companies must capitalize those costs and amortize them over 5 years for domestic research (15 years for foreign). A company spending $2 million annually on domestic R&D can deduct only roughly $200,000 in year one under the half-year convention — significantly raising cash taxes even for businesses that are economically losing money. Bipartisan legislation to restore immediate expensing (HR 1990, S 1639) has passed the House with overwhelming margins but stalled in the Senate over revenue offsets. For companies that also invest in physical assets, the interaction with manufacturing incentives (CHIPS Act credits, IRA Section 45X) can partially offset the R&D timing burden.

For eligible startups, the payroll tax offset is one of the most underutilized provisions in the tax code: companies with $5 million or less in gross receipts that had no revenue before the 5-year lookback period can apply up to $500,000 of R&D credit against FICA payroll tax — directly reducing cash obligations even before the business turns a profit. R&D expensing restoration and bonus depreciation are frequently packaged together in reform proposals; see also Section 179 expensing for related write-off rules.

How It Affects You

Implementing Regulations

• 26 CFR Part 1 — Income tax regulations (section 1.174: research and experimental expenditure definitions, general rules, allocation/apportionment for R&E expenses)

Pending Legislation (119th Congress)

• HR 1990 (Rep. Estes, R-KS) — American Innovation and R&D Competitiveness Act of 2025. Would let firms immediately deduct research costs or amortize certain capitalized R&E over 60 months and align deduction rules with the R&D tax credit. Status: Introduced.
• S 1639 (Sen. Young, R-IN) — American Innovation and Jobs Act. Restores immediate expensing for research costs, offers a 60-month amortization option, and clarifies how R&D deductions work with the research tax credit. Status: Introduced.

Recent Developments

Section 174 amortization restoration is the highest-priority business tax fix in the 119th Congress. The Tax Relief for American Families and Workers Act passed the House 357-70 in February 2024 with §174 immediate expensing restoration retroactive to tax year 2022 — an unusually lopsided bipartisan vote reflecting the breadth of affected industries, from pharmaceutical companies doing drug development to agriculture technology firms to defense contractors. The bill stalled in the Senate, where revenue offset disagreements blocked action. Bipartisan bills HR 1990 and S 1639 in the 119th Congress (2025-2026) would restore immediate expensing and make the change permanent — but face the same revenue offset problem: retroactive restoration for 2022-2025 alone would cost approximately $100-150 billion in foregone revenue over 10 years, which must be paid for in a Congress focused on deficits. The OBBB Act (2025) addressed many business tax priorities but did not include §174 restoration, leaving it as the most prominent unfinished item in the business tax agenda.

IRS guidance on what must be capitalized under §174 has expanded the provision's reach beyond what many companies expected. Notice 2023-63 and Notice 2024-12 require capitalization of virtually all costs related to "research or experimental expenditures" — including developer wages, laboratory supplies, overhead allocations, and software development costs that were previously immediately deductible under Rev. Proc. 2000-50. The broad interpretation covers software companies that were writing off engineer salaries under the old software development safe harbor: under current IRS interpretation, those salaries must now be capitalized and amortized. Several large technology companies and their trade associations have publicly criticized the guidance as exceeding congressional intent and have submitted comments requesting narrower standards. IRS has not yet finalized a permanent rule to replace the interim notices, leaving companies in ongoing uncertainty about scope.

The expanded payroll tax offset provision — raised from $250,000 to $500,000 by the Inflation Reduction Act and applicable to startups with $5 million or less in gross receipts — is reaching more companies as awareness grows. For a pre-revenue software startup burning $1.5 million annually in engineer salaries developing a new product, the FICA payroll tax alone runs roughly $110,000-$130,000. A $500,000 R&D credit offsets most or all of that, reducing cash burn by $100,000+ per year even before the company has a dollar of taxable income. Tax preparers and startup CPAs who specialize in R&D credit analysis report that a significant share of startups eligible for the payroll tax offset are still not claiming it — either because their advisors don't specialize in R&D credits or because the four-part qualification test seems complex. The credit calculation itself (qualifying wages × applicable rate) is relatively straightforward once qualifying activities are identified; the harder part is the contemporaneous documentation requirement that IRS expects to support a credit claim on audit.